The success of systemic standard‐of‐care chemotherapy in PDAC patients is disappointingly low.[15, 48] Cancer cells develop chemoresistance, enabling them to survive and grow.[48] In PDAC patients, immunosuppressive myeloid cells populate the tumor area, mediating T cell exclusion, resistance to immune checkpoint inhibition, and poor clinical prognosis.[10, 11] Targeting myeloid cells by activating CD11b signaling is a promising approach for immune checkpoint therapies. Here, ITGAM is linked to cancer.